Biotechs risk reward is high, getting a drug to trial and then passed can lead to huge success for investors. Of the top 10 stocks in the U.S. for 2017 8 are biotechs. Failure and there are many busts along the way.
Biotechs risk reward is high, getting a drug to trial and then passed can lead to huge success for investors. Of the 10 best performing stocks in the U.S. for 2017 8 were biotechs. Failure and there are many busts along the way. The other two were $CIFS, a Chinese Internet company and cord cutter $ROKU.
Biotechs are not for everyone and balance is key in risk management. Of the seven worst IPOs in 2017, three out of seven were biotech of the top five IPOs in 2017, three are biotechs. Clearly it is important to be on the ‘right horse’.
Top 10 Performing Stocks in 2017 on the United States Stock Markets*
*Stocks must trade 100,000 shared per pay on average.
2. Madrigal Pharma $MDGL +516%
3. Esperion Therapeutics $ESPR +425.90%
4. Nektar Therapeutics $NKTR +386.70%
5. China Internet Natw Financial $CIFS +319.50%
6. Exact Sciences $EXAS +293.30%
7. Foundation Medecine $FMI +285.30%
8. Assembly Biosciences $ASMB +272.40%
9. Argenx SE $ARGX +271.40%
Live From The Pit